BioArctic AB

Total Valuation

BioArctic AB carries a market capitalization of 2.61B, placing it among publicly traded companies globally. Its enterprise value stands at 28.21B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

BioArctic AB currently has 88.72M shares outstanding.

Valuation Ratios

BioArctic AB trades at a trailing price-to-earnings ratio of 285.05. The price-to-sales ratio is 30.00, and the price-to-book ratio stands at 14.93.

Enterprise Valuation

On an enterprise value basis, BioArctic AB trades at an EV/EBITDA multiple of 135.07 and an EV/FCF ratio of 113.80. The EV/Sales ratio of 28.14 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 135.07 provides insight into valuation relative to core operating earnings.

Financial Position

BioArctic AB maintains a current ratio of 3.99, meaning it holds 4.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 4.49, indicating elevated leverage, while an interest coverage ratio of 22.93 demonstrates strong ability to service its debt obligations.

Financial Efficiency

BioArctic AB posts a return on equity of 5.21 and a return on invested capital of 4.23.

Taxes

Over the trailing twelve months, BioArctic AB has paid 143.11M in income taxes, reflecting an effective tax rate of 57.56.

Stock Price Statistics

BioArctic AB's stock has declined approximately -8.58209% over the past 52 weeks. The 50-day moving average sits at 34.33, while the 200-day moving average is 34.05.

Income Statement

Over the trailing twelve months, BioArctic AB generated 1.00B in revenue and converted that into 105.52M in net income, yielding earnings per share of 1.19. EBITDA reached 208.82M, while operating income came in at 208.82M.

Balance Sheet

BioArctic AB holds 1.99B in cash and equivalents against 90.61M in total debt, resulting in a net debt position of -1.08B. Total book value stands at 2.02B, with working capital of 2.01B providing operational flexibility.

Cash Flow

BioArctic AB produced 243.98M in operating cash flow over the past twelve months.

Margins

BioArctic AB operates with a gross margin of 93.17, reflecting its pricing power and cost economics. The operating margin of 20.83 and net profit margin of 10.53 provide insight into operational efficiency.

Dividends & Yields

Scores

BioArctic AB posts an Altman Z-Score of 23.95, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.